Prospective study on the effects of rituximab on synovial tissue of patients with rheumatoid arthritis

Completed

• Conditions: Rheumatoid arthritis; Musculoskeletal Diseases; Arthropathies

• Registration Number: ISRCTN05568900
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06-27
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

1. Patients (18 years or older) with rheumatoid arthritis (American College of Rheumatology [ACR] 1987 criteria) with active disease (at least 4/28 swollen and at least 4/28 painful joints, and either Erythrocyte Sedimentation Rate [ESR] 28 mm or C-Reactive Protein [CRP] 15 mg/l or morning stiffness for 45 minutes)
2. Rheumatoid factor and/or anti-Cyclic Citrullinated Peptide antibody (anti-CCP) positive
3. Stable doses of methotrexate (5 - 30 mg)
4. Stable doses of prednisone (0 - 10 mg)
5. Previous anti-Tumour Necrosis Factor (anti-TNF) treatment is allowed

Exclusion Criteria

1. Previous treatment with rituximab
2. Intra-articular or parenteral corticosteroids within four weeks prior to inclusion

Study & Design

• Study Type: Interventional
• Study Design: Not specified